Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1974-1983

  Frenkel, Yulia Volovik ^a   Clark Jr , Arthur D ^a   Das, Kalyan ^a   Wang, Yuh Hwa ^b   Lewi, Paul J ^c   Janssen, Paul A J ^c   Arnold, Eddy ^a  

^a RUTGERS UNIVERSITY   (United States)

^b University of Medicine and Dentistry   (United States)

^c Center for Molecular Design   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAVIRINE; DAPIVIRINE; ETRAVIRINE; R106168; R120393; R124043; R126874; R129385; R132914; R138750; R152649; R152929; R156204; R157753; R185545; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON MICROSCOPY; GASTROINTESTINAL ABSORPTION; HUMAN; HYDROPHOBICITY; LIGHT SCATTERING; NONHUMAN; PH MEASUREMENT; PHYSICAL CHEMISTRY; PKA; PROTEIN AGGREGATION; RAT; STRUCTURE ACTIVITY RELATION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHYSICAL; GASTROINTESTINAL TRACT; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROPHOBICITY; LIGHT; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; PYRIMIDINES; RATS; REVERSE TRANSCRIPTASE INHIBITORS; SCATTERING, RADIATION; SOLUTIONS; TRIAZINES;

EID: 15444366107     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049439i     Document Type: Article

References (53)

1. Ahr, G.; Voith, B.; Kuhlmann, J. Guidances related to bioavailability and bioequivalence: European industry perspective. Eur. J. Drug Metab. Pharmacokinet. 2000, 25, 25-27.
2. Rosenberg, S. H.; Spina, K. P.; Condon, S. L.; Polakowski, J.; Yao, Z.; Kovar, P.; Stein, H. H.; Cohen, J.; Barlow, J. L.; Klinghofer, V.; et al. Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3-[[(1-methylpiperazin-4-yl)sulfonyl]propionyl] -3-thiazol-4-yl-L-alanine amide of (2S, 3R,4S)-2-amino-1-cyclohexyl-3,4- dihydroxy-6-methylheptane (A-72517). J. Med. Chem, 1993, 36, 460-467.
3. Rosenberg, S. H.; Spina, K. P.; Woods, K. W.; Polakowski, J.; Martin, D. L.; Yao, Z.; Stein, H. H.; Cohen, J.; Barlow, J. L.; Egan, D. A.; et al. Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. J. Med. Chem. 1993, 36, 449-459.
4. Martinez, M. N.; Amidon, G. L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 2002, 42, 620-643.
5. Li, A. P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today 2001, 6, 357-366.
6. Li, A. P. Advancing technologies for accelerated drug development. Drug Discovery Today 2003, 8, 200-202.
7. White, R. E. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 133-157.
8. Caldwell, G. W.; Easlick, S. M.; Gunnet, J.; Masucci, J. A.; Demarest, K. In vitro permeability of eight beta-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J. Mass Spectrom. 1998, 33, 607-614.
9. Larger, P.; Altamura, M.; Catalioto, R. M.; Giuliani, S.; Maggi, C. A.; Valenti, C.; Triolo, A. Simultaneous LC-MS/MS determination of reference pharmaceuticals as a method for the characterization of the Caco-2 cell monolayer absorption properties. Anal. Chem. 2002, 74, 5273-5281.
10. Fung, E. N.; Chu, I.; Li, C.; Liu, T.; Soares, A.; Morrison, R.; Nomeir, A. A. Higher-throughput screening for Caco-2 permeability utilizing a multiple sprayer liquid chromatography/ tandem mass spectrometry system. Rapid Commun. Mass Spectrom. 2003, 17, 2147-2152.
11. Yu, L. X.; Lipka, E.; Crison, J. R.; Amidon, G. L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Delivery Rev. 1996, 19, 359-376.
12. Junginger, H. E.; Hoogstraate, J. A.; Verhoef, J. C. Recent advances in buccal drug delivery and absorption - in vitro and in vivo studies. J. Controlled Release 1999, 62, 149-159.
13. Pidgeon, C.; Ong, S.; Liu, H.; Qiu, X.; Pidgeon, M.; Dantzig, A. H.; Munroe, J.; Hornback, W. J.; Kasher, J. S.; Glunz, L.; et al. IAM chromatography: an in vitro screen for predicting drug membrane permeability. J. Med. Chem. 1995, 38, 590-594.
14. Ungell, A. L.; Nylander, S.; Bergstrand, S.; Sjoberg, A.; Lennernas, H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci. 1998, 87, 360-366.
15. Ansede, J. H.; Thakker, D. R. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J. Pharm. Sci. 2004, 93, 239-255.
16. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
17. Lipka, E.; Amidon, G. L. Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J. Controlled Release 1999, 62, 41-49.
18. Jani, P.; Halbert, G. W.; Langridge, J.; Florence, A. T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 1989, 41, 809-812.
19. Hodges, G. M.; Carr, E. A.; Hazzard, R. A.; Carr, K. E. Uptake and translocation of microparticles in small intestine. Morphology and quantification of particle distribution. Dig. Dis. Sci. 1995, 40, 967-975.
20. Chen, H.; Langer, R. Oral particulate delivery: status and future trends. Adv. Drug Delivery Rev. 1998, 34, 339-350.
21. Kraehenbuhl, J. P.; Neutra, M. R. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 2000, 16, 301-332
22. Eldridge, J. H.; Meulbroek, J. A.; Staas, J. K.; Tice, T. R.; Gilley, R. M. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv. Exp. Med. Biol. 1889, 251, 191-202.
23. Desai, M. P.; Labhasetwar, V.; Amidon, G. L.; Levy, R. J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13, 1838-1845.
24. Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 11 (Suppl. 2), S73-S80.
25. Kostewicz, E. S.; Brauns, U.; Becker, R.; Dressman, J. B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res. 2002, 19, 345-349.
26. Charman, W. N. A.; Stella, V. J. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 1986, 34, 175-178.
27. Charman, W. N. A., Stella, V. J., Eds. Lymphatic Transport of Drugs; CRC Press: Boca Raton, FL, 1992.
28. Ikomi, F.; Hanna, G. K.; Schmid-Schonbein, G. W. Size- and surface-dependent uptake of colloid particles into the lymphatic system. Lymphology 1999, 32, 90-102.
29. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
30. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
31. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
32. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Bethune, M. P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
33. Janssen, P. A. J.; Lewi, P.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, H. M.; Guillemont, J.; Pasquier, E.; Kukla, M. J.; Ludovici, D. W.; Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile (R278474, Rilpivirine). J. Med. Chem., in press.
34. Ludovici, D. W.; Kavash, R. W.; Kukla, M. J.; Ho, C. Y.; Ye, H.; De Corte, B. L.; Andries, K.; de Bethune, M. P.; Azijn, H.; Pauwels, R.; Moereels, H. E.; Heeres, J.; Koymans, L. M.; de Jonge, M. R.; Van Aken, K. J.; Daeyaert, F. F.; Lewi, P. J.; Das, K.; Arnold, E.; Janssen, P. A. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2229-2234.
35. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M. P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M.; de Jonge, M. R.; Van Aken, K. J.; Daeyaert, F. F.; Das, K.; Arnold, E.; Janssen, P. A. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
36. Sankatsing, S. U.; Weverling, G. J.; Peeters, M.; van't Klooster, G.; Gruzdev, B.; Rakhmanova, A.; Danner, S. A.; Jurriaans, S.; Prins, J. M.; Lange, J. M. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003, 17, 2623-2627.
37. Gruzdev, B.; Rakhmanova, A.; Doubovskaya, E.; Yakovlev, A.; Peeters, M.; Rinehart, A.; de Dier, K.; Baede-Van Dijk, P.; Parys, W.; van't Klooster, G. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003, 17, 2487-2494.
38. Andries, K.; Azijn, H.; Thielemans, T.; Ludovici, D.; Kukla, M.; Heeres, J.; Janssen, P.; De Corte, B.; Vingerhoets, J.; Pauwels, R.; de Bethune, M. P. TMC125, a novel next-generation non-nucleoside reverse transcriptase inhibitor active against non-nucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48, 4680-4686.
39. Lewi, P.; Arnold, E.; Andries, K.; Bohets, H.; Borghys, H.; Clark, A.; Daeyaert, F.; Das, K.; de Bethune, M. P.; de Jonge, M.; Heeres, J.; Koymans, L.; Leempoels, J.; Peeters, J.; Timmerman, P.; Van den Broeck, W.; Vanhoutte, F.; Van't Klooster, G.; Vinkers, M.; Volovik, Y.; Janssen, P. A. Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds. Drugs R&D 2004, 5, 245-257.
40. Raschke, T. M.; Tsai, J.; Levitt, M. Quantification of the hydrophobic interaction by simulations of the aggregation of small hydrophobic solutes in water. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5965-5969.
41. DynaPro-MS800, version 5.26.60; Protein Solutions, Inc.: Lakewood, NJ, 2000.
42. JMP Statistical Discovery Software, version 3.1; SAS Institute Inc.: Cary, NC, 1995.
43. Regev, O.; Zana, R. Aggregation behavior of tyloxapol, a nonionic surfactant oligomer, in aqueous solution. J. Colloid Interface Sci. 1999, 210, 8-17.
44. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
45. Neuhoff, S.; Ungell, A. L.; Zamora, I.; Artursson, P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 2003, 20, 1141-1148.
46. Kostewicz, E. S.; Wunderlich, M.; Brauns, U.; Becker, R.; Bock, T.; Dressman, J. B. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol. 2004, 56, 43-51.
47. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45, 1712-1722.
48. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 2003, 46, 4265-4272.
49. Pacheco, L. F.; Carmona-Ribeiro, A. M. Effects of synthetic lipids on solubilization and colloid stability of hydrophobic drugs. J. Colloid Interface Sci. 2003, 258, 146-154.
50. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 2003, 46, 4477-4486.
51. Forssell, H. Gastric mucosal defence mechanisms: a brief review. Scand. J. Gastroenterol., Suppl. 1988, 155, 23-28.
52. Camilleri, M.; Colemont, L. J.; Phillips, S. F.; Brown, M. L.; Thomforde, G. M.; Chapman, N.; Zinsmeister, A. R. Human gastric emptying and colonic filling of solids characterized by a new method. Am. J. Physiol. 1989, 257, G284-G290.
53. Waterman, K. C.; Sutton, S. C. A computational model for particle size influence on drug absorption during controlled-release colonic delivery. J. Controlled Release 2003, 86, 293-304.